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Abstract
Recently, it has been shown that human ejaculate enhances human immunodeficiency virus 1 (HIV-1) infectivity.
Enhancement of infectivity is conceived to be mediated by amyloid filaments from peptides that are proteolytically
released from prostatic acid phosphatase (PAP), termed Semen-derived Enhancer of Virus Infection (SEVI). The aim
of this study was to test the range of HIV-1 infectivity enhancing properties of a large number of individual semen
samples (n = 47) in a TZM-bl reporter cell HIV infection system. We find that semen overall increased infectivity to
156% of the control experiment without semen, albeit with great inter- and intraindividual variability (range -53%-
363%). Using transmission electron microscopy, we provide evidence for SEVI fibrils in fresh human semen for the
first time. Moreover, we confirm that the infectivity enhancing property can be inhibited by the major green tea
ingredient epigallocatechin-3-gallate (EGCG) at non-toxic concentrations. The median inhibition of infection by
treatment with 0.4 mM EGCG was 70.6% (p < 0.0001) in our cohort. Yet, there were substantial variations of
inhibition and in a minority of samples, infectivity enhancement was not inhibited by EGCG treatment at all. Thus,
topical application of EGCG may be a feasible additional measure to prevent the sexual transmission of HIV.
However, the reasons for the variability in the efficacy of the abrogation of semen-mediated enhancement of HIV-1
infectivity and EGCG efficacy have to be elucidated before therapeutic trials can be conducted.
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Background
HIV-infection is an imminent health issue, with an esti-
mated 33 million individuals infected worldwide accord-
ing to UNAIDS [1]. Globally, most HIV infections occur
by heterosexual transmission (for review see [2]). Sexual
HIV-1-transmission depends on viral and multiple host
factors that altogether have not been entirely unraveled
[3], and a direct role of semen has been described by
several groups (reviewed in [4]).
Recently, it has been reported that human ejaculate acts
as a potent enhancer of HIV infectivity [5]. This enhance-
ment of infectivity is mediated by a factor, termed Semen-
derived Enhancer of Virus Infection (SEVI) [5]. SEVI was
identified to be a peptide fragment of the semen marker
prostatic acidic phosphatase (PAP) that, upon proteolytic
release, forms amyloid fibrils. These fibrils capture HIV
virions and direct them to target cells, where they facilitate
the fusion of virus and host cell [6].
Interestingly, it has been previously demonstrated that
epigallocatechin-3-gallate (EGCG), the major active con-
stituent of green tea, can inhibit the infectivity enhan-
cing effect of SEVI, possibly by interference with de
novo SEVI formation or by degradation of present pre-
formed PAP-derived amyloid fibrils [7]. This observation
may be important for possible application of EGCG in
microbicidal vaginal and rectal gels that could reduce
HIV transmission rates [8,9].
To date, published studies on SEVI (and EGCG) are pre-
dominantly based on in vitro experiments carried out
either with pooled human semen or with fibrils formed
from synthetic PAP-fragment peptides (PAP248-286)
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mine the range and variability of the HIV-1 infectivity
enhancing properties and the effect of EGCG on infectivity
enhancement within a cohort of individual human semen
samples, and to describe the clinical semen characteristics
that are potentially associated with the augmentation of
HIV-1-infectivity. In addition, this is the first study that
provides evidence for the presence of SEVI fibril structures
in human semen by transmission electron microscopy.
Results
Individual semen samples enhance HIV-1 infection
47 individual semen samples, originating from HIV-1
negative, clinically infertile men and healthy donors
were analyzed. Full spermiograms according to the cri-
teria of the WHO (1999) [10] and routine laboratory
parameters were determined for all samples. All donors
gave written informed consent for this study that was
approved by the local ethics committee. To assess the
HIV-1-infectivity enhancing properties of all individual
semen samples, TZM-bl reporter cells were infected
with HIV-1 BaL that was preincubated in the presence
or absence of semen. Infection levels were then deter-
mined by measuring luciferase activity. A detailed over-
view of the experimental design is depicted in Figure 1.
Our first major finding is, that the majority of semen
samples enhance HIV-1 infectivity (Figure 2). However,
there was considerable heterogeneity in the infectivity
enhancing properties, and a minority of semen samples
(6/47) even caused a slight decrease in HIV-1 infectivity.
On average, the infection rate was enhanced to 155.7%
(range -53%-363%) of the control experiment in absence
of semen.
All clinical semen parameters were tested with respect
to the infectivity enhancing properties and moderate
correlations with two clinical semen-parameters were
noticed (Figure 3): The ejaculate volume (r = 0.3455, p
= 0.0201), and the concentration of zinc (r = 0.3303, p
= 0.0267) correlated positively with enhancement of
infection at univariate analysis. Of note, the ejaculate
volume did not correlate with days of sexual abstinence.
Other analyzed semen parameters (proportions of
mobile and immobile spermatozoa, number of round
cells, pH, concentrations of fructose, zinc, citrate and
carnitine) did not correlate significantly with the
enhancement of HIV-1 infection, although there was a
trend towards a positive correlation with the concentra-
tion of citrate (r = 0.2510, p = 0.0963). It will be impor-
tant to test in subsequent studies, whether any of these
parameters could have some influence on amyloid fibril-
logenesis in semen or the rate of SEVI-degradation. The
minority of samples that inhibited infectivity did not
share an obvious clinical characteristic or parameter.
Semen contains fibrils resembling synthetic SEVI fibrils
It has been demonstrated that the chemically synthe-
sized PAP-fragment PAP248-286 forms amyloid fibrils
(SEVI fibrils) [5], which have been visualized by
Figure 1 Schematic outline of the experimental procedure.
Mean=155.7%
Figure 2 HIV-1 infectivity enhancing properties of human
semen samples. 47 semen samples were analyzed for HIV-1-
infectivity modulating effects. Results are arranged by infectivity
enhancing potency. Semen was used in a 1:16 dilution during
preincubation. The Y-axis denotes the infection rate relative to
control infections performed without semen (depicted as dotted
line) as percentage. Shown are mean values of quintuplicate
infections. Error bars represent the standard error of the means.
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semen samples to date have not been analyzed for the
presence of fibrils. We therefore subjected a human
semen sample and an agitated solution of PAP248-286
containing SEVI fibrils to TEM. Inspection of the corre-
sponding micrographs revealed the presence of large
fibrils in the semen sample (Figure 4). These fibrils
r a n g ei ns i z ef r o m3 0 0n mt oa b o u t3μma n dc l o s e l y
resemble synthetic SEVI-fibrils formed from PAP248-
286.
Semen-mediated enhancement of HIV-1 infectivity is
abrogated by EGCG at non-toxic concentrations in the
large majority of semen samples
In a next step, inhibition of the infectivity enhancing
effect of semen by preincubation with EGCG was tested
within the entire cohort (Figure 5A). An EGCG concen-
tration of 0.4 mM was chosen to rule out toxicity in our
assay (Figure 5B). We find, that for the majority of
semen samples, the augmentation of HIV-1 infection
was indeed drastically inhibited by treatment with
EGCG. This effect was concentration dependent (Figure
5C). Overall, EGCG treatment decreased the infection
rate by a median of 70.6% (p < 0.0001). However, we
observed substantial heterogeneity for the inhibition of
semen-mediated enhancement of HIV infection by
EGCG (range -111%-98%). EGCG had an inhibitory
effect on only 41 of the 47 samples.
To validate the inhibitory effect of EGCG, we also
subjected a pool of all 47 analyzed semen samples to
the infection assay in presence or absence of EGCG.
Pooled semen increased the infection rate to 124% and
EGCG treatment lead to a complete abrogation of the
infectivity enhancement by pooled semen. Of note, the
rate of HIV-1 infection enhancement by pooled semen
samples was slightly lower than the mean of measure-
ments for the individual samples.
Direct EGCG toxicity at doses used to block enhance-
ment of infectivity (0.4 mM) was ruled out in a [
3H]-
thymidin incorporation assay and in a flow cytometry-
based apoptosis/necrosis assay utilizing Annexin-V and
7-AAD (Figure 5B).
We next wanted to verify the efficacy of EGCG treat-
ment for synthetic SEVI. Synthetic SEVI enhanced HIV-
infectivity drastically, leading to a 40-fold (4000%)
increase in the infection rate in our assay when applied
in a concentration of 250 μg/ml. Treatment with 0.4
mM EGCG completely abolished this effect (Figure 5D).
To test the efficacy of EGCG under experimental con-
ditions that better reflect the in vivo situation, we incu-
bated TZM-Bl cells directly with semen from an HIV-
positive, highly viremic donor in presence or absence of
0.4 mM EGCG (Figure 6A). This approach resulted in
successful infection and EGCG-treatment led to a 55%
reduction of the infectivity of autologous virus/semen (p
= 0.0033).
To elucidate whether semen-mediated enhancement
of HIV-1 infectivity and its inhibition by EGCG was
dependent on certain viral strains and/or viral corecep-
tor tropism, a panel of three different HIV-1 strains and
four individual semen samples were tested (Figure 6B).
We observed a similar pattern for all three viral strains
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Figure 3 Infectivity enhancing potential of semen samples correlates with clinical semen parameters. Ejaculate volume (A) and zinc
concentration (B) were plotted against the enhancement of HIV-1 infectivity. Correlations were determined using the two-tailed Pearson
correlation coefficient.
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Page 3 of 9tested. Measured values for X4-tropic NL4/3 and pri-
mary HIV-1B isolate in absence of EGCG differ by 35%
and 25% respectively from the infectivity enhancement
observed for R5-tropic BaL. EGCG-treatment reduced
the infectivity of all analyzed viruses in presence of each
of the investigated semen samples, albeit to varying
degrees. The results of these experiments confirm the
interindividual spread of the infectivity enhancing effect
in semen and its inhibition by EGCG for X4- and R5-
tropic laboratory strains and for a primary HIV-1B
isolate.
The infectivity enhancing potential and clinical
parameters of semen vary between different samples
from identical donors
Longitudinal analysis showed that the infectivity
enhancing effect varies within semen samples originat-
ing from the same donors. We observed variation up
to 45% (Figure 7A and 7B). There was also substantial
v a r i a t i o ni nt h ec o m p o s i t ion of the samples (Figure
7B). Concentrations of zinc and citrate differed up to
900% and 600% respectively between samples from
identical donors.
Semen PAP248–286 
6,300 x
35,000 x
Figure 4 Transmission electron microscopy analysis of semen and synthetic SEVI in a closed system. A fresh semen sample and a
solution of chemically synthesized SEVI (PAP-fragment PAP248-286) were analyzed as described in the methods section. The bottom images
depict a detail (magnification: 35,000 ×) of the above electron micrographs (magnification: 6,300 ×). The semen sample shows a high density of
fibrils with lengths ranging from 300 nm to about 3 μm, that exhibit a clear resemblance to the fibrils formed from chemically synthesized SEVI
(PAP-fragment PAP248-286). The synthetic SEVI fibrils frequently run out of pane due to the embedding angle. Arrows indicate typical fibril
structures.
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The aim of this study was to analyze the infectivity
enhancing properties of a large number of individual
human semen samples. We show that individual semen
samples overall significantly enhance HIV-1 infection in
vitro. We could also directly visualize fibrils in human
semen, which resemble fibrils formed from synthetic
PAP248-286 by transmission electron microscopy. For
the majority of semen samples, the enhancement of
HIV-1 infection can be drastically inhibited by treatment
with non-toxic concentrations of EGCG, a small-mole-
cule inhibitor of amyloid fibrillogenesis [11] (median
inhibition = 70.6%, p < 0.0001). The efficacy of EGCG
as an inhibitor of semen-mediated infectivity enhance-
ment was confirmed for pooled semen, for autologous
virus/semen from an HIV-positive, highly viremic donor
and for synthetic SEVI.
Kim et al. recently demonstrated that HIV-1 infectivity
enhancement by semen is highly heterogeneous [12].
Here we confirm and extend their finding that the abil-
ity of individual semen samples to enhance in vitro
HIV-1 infection differs considerably. A minority of sam-
ples even inhibited infectivity in our experimental setup.
We show that the HIV-1 infectivity enhancing potency
is variable even in longitudinal semen samples originat-
i n gf r o mt h es a m ed o n o ro b t a i n e da td i f f e r e n tt i m e
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Figure 5 EGCG abrogates semen-enhanced viral infection and the effect of synthetic SEVI at nontoxic concentrations. A) 47 individual
semen samples were preincubated separately and pooled in presence or absence of 0.4 mM EGCG and subjected to the infection assay as
described in the methods section. Semen was used in a 1:16 dilution during preincubation. The Y-axis denotes the infection rate as percent in
relation to control infections performed without semen. Data points represent mean values of quintuplicate infections, black lines show the
mean values for all samples and standard error of the means. Red lines show the results for pooled semen. The indicated p-value is the result of
a paired, two-tailed Student’s t-test analysis. B) Cellular viability in presence of EGCG was tested in a [
3H]-thymidin incorporation assay. Data is
expressed as counts per minute, shown are mean values of quintuplicate measurements. Error bars represent the standard error of the means.
The insertion figure shows the results of a flow cytometry-based apoptosis/necrosis assay utilizing Annexin-V and 7-AAD. The Y-axis denotes the
percentage of Annexin V
+, 7-AAD
+ and double positive cells. C) A random individual semen sample was subjected to the infection assay as
described above in presence of increasing EGCG concentrations. D) Synthetic SEVI (250 μg/ml) in presence or absence of 0.4 mM EGCG was
subjected to the infection assay as described above. The indicated p-value is the result of a paired, two-tailed Student’s t-test analysis.
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Page 5 of 9points. This finding underscores the high degree of het-
erogeneity and fluctuations of semen properties, which
will pose a significant problem for future interventional
trials.
We also used a panel of three different X4- and R5-
tropic HIV-1 strains in our experiments, thereby con-
firming that the infectivity enhancing effect in semen is
independent of the viral coreceptor tropism (Figure 6B).
Synthetic SEVI enhanced HIV-1 infectivity about 25 fold
stronger than semen in our experimental setup (Figure
5D). This does not contradict our results for semen, as
the employed concentration of synthetic SEVI (250 μg/
ml) was unphysiologic and much higher than the esti-
mated concentration of SEVI in semen (35 μg/ml, as
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Figure 6 EGCG effectively inhibits semen-enhanced viral infection of autologous virus/semen and R5- as well as X4-tropic viruses. A)
Semen samples from a healthy donor and an HIV-1-positive patient with high viremia were preincubated in presence or absence of 0.4 mM
EGCG and subjected to the infection assay as described in the methods section. Semen was used undiluted during preincubation. Columns
represent luciferase activity minus background (luciferase activity in control experiments performed without semen) expressed as RLU/s*1000.
Error bars represent the standard error of the means. The indicated p-values result from unpaired, two-tailed Student’s t-test analysis. Significantly
higher luciferase activity in cells incubated with semen from the HIV-patient than in cells incubated with semen from the healthy donor
demonstrates successful infection. B) To analyze semen-mediated enhancement of HIV-1 infectivity and its inhibition by EGCG with regards to
different virus strains, three different HIV-1 strains were deployed: BaL (R5-tropic), NL4/3 (X4-tropic) and a primary HIV-1B isolate. Four individual
semen samples were subjected to the infection assay described above in presence or absence of 0.4 mM EGCG.
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Figure 7 Variation of infectivity enhancing potential and clinical parameters of semen between different samples from identical
donors. Semen samples from two healthy donors were analyzed longitudinally. A) Infectivity modulation in relation to control infections
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Page 6 of 9estimated by Münch et al. [5]). However, these results
demonstrate the great potential of synthetic SEVI as an
enhancer of in vitro lentiviral infection rates [13].
In contrast to our results, Kim et al. observed overall
greater semen-mediated enhancement of HIV-1 infectiv-
ity (ranging from 2 to about 50-fold) [12], most likely
due to differing experimental conditions and amounts of
HIV-virions used for infection. We observed a strong
dependence of the absolute HIV-infectivity enhancement
on the amount of inoculum (semen-mediated enhance-
ment is approximately threefold stronger when 20 pg
BaL-p24 are used for infection instead of the utilized
100 pg). However, the experimental conditions for our
study were chosen to ensure maximal test reliability and
allow reproducible, consistent results.
In the above mentioned study, Kim et al. have demon-
strated that semen-mediated HIV-1 infectivity enhance-
ment correlates with SEVI/PAP248-286 levels measured
by ELISA utilizing antisera from guinea pigs and rabbits
[12]. Centrifugation through a 100-kDa-pore-size filter
removed the entire virus enhancing activity and the
reactivity to anti-SEVI antiserum, demonstrating that
the enhancing factor has a molecular weight of > 100
kDa, which is in agreement with the fibril hypothesis of
infectivity enhancement. A correlation between fibril
abundance and HIV-1 infectivity enhancement was also
demonstrated by Hauber et al. for synthetic SEVI fibrils,
quantified by Congo red staining [7].
Possible causes for the observed heterogeneity of the
HIV-infectivity enhancing potency of semen, besides the
amount of SEVI fibrils present, could be the variable
abundance of cationic polypeptides that inhibit HIV-1
infection [14] and/or naturally occurring proteases in
semen. In a recent study, Martellini et al. show that
human seminal plasma inhibits fibril formation of
PAP248-286 and exhibits proteolytic activity that can
inhibit the proviral activity of SEVI under certain condi-
tions [15]. Interestingly, we found a positive correlation
between HIV-1 infectivity enhancement and the concen-
tration of zinc in semen by univariate analysis. The find-
ings of Martellini et al. could offer an explanation for
this correlation. As Zn
2+ exhibits inhibitory effects on
semen proteases [16], it is intruiging to hypothesize that
SEVI fibrils could be more stable in semen samples that
contain high amounts of Zn
2+, and thus tend to have a
higher capacity to enhance HIV infectivity.
Our results confirm and extend the original findings
by Hauber et al., who first described the inhibition of
semen-mediated enhancement of HIV-infectivity by
EGCG for a limited number of individual semen sam-
ples [7]. While it was thought that the SEVI inhibiting
effect by EGCG is mainly mediated through its anti-
fibrillogenic properties, we also observed semen-inde-
pendent inhibition of HIV-infectivity at non-toxic
EGCG concentrations. For some samples and for the
pool of all samples, the infection rate in presence of
EGCG and semen was reduced to below the infection
rate of control experiments performed in absence of
EGCG and semen. To elucidate this effect, we tested the
direct antiviral activity of EGCG in absence of semen in
our assay. In contrast to previous results by Hauber et
al. with Jurkat 1G5 cells and HIV-1 NL4/3 [7], we
observed a semen-independent inhibition of HIV-infec-
tivity by EGCG. The presence of 0.4 mM EGCG in
absence of semen resulted in 88.5% inhibition of HIV
infectivity. Several other studies also found a direct inhi-
bition of HIV-infectivity by EGCG, albeit in different
cells [17-20]. This inhibition is thought to be mediated
through direct interaction with the CD4 receptor and/or
HIV-1 Env. A direct antiviral activity of EGCG has also
been described for other viruses, namely herpes simplex
virus (HSV) [21] and hepatitis C virus (HCV) [22]. Cie-
sek et al. recently demonstrated that EGCG is an inhibi-
tor of hepatitis C virus entry [22]. Regardless of the
mechanism, EGCG treatment effectively abolished
enhancement of HIV-1 infectivity of the majority of
individual semen samples, of pooled semen, and of syn-
thetic SEVI in our experimental setup. Direct inhibition
of the infectivity of HIV and other viruses by EGCG
would be an additional advantage for its use in antiviral
microbicides.
Clinically, the systemic administration of EGCG has
been proven to be safe and well tolerated in several stu-
dies [23-26]. Topical application of EGCG has been
tested in mice with no dermal toxicity detected after
ointment application (up to 3% w/w) daily for 30 days
[27]. 3% w/w EGCG corresponds to a concentration of
65.5 mM, more than 100-fold higher than the effective
concentration used in our assay for inhibition of semen-
mediated enhancement of HIV infection. Its safety and
low cost together with its effects on other pathogens
such as HSV [21] could make EGCG an attractive addi-
tional supplement for antimicrobial gels.
In agreement with Münch et al., it has to be pointed
out that our results may underestimate the potency of
SEVI for in vivo infectivity enhancement [5]. The quan-
tity of HIV-1 virions transmitted during sexual inter-
course is considerably lower than the amount of virions
used in our assay, and the relative HIV-infectivity
enhancement strongly depends on the amount of inocu-
lum. Testing of semen-mediated enhancement of HIV-1
infection in animal models is warranted to clarify its
role in sexual transmission of HIV-1.
In summary, we demonstrate for the first time that
fresh human semen contains fibrils with clear resem-
blance to fibrils formed from synthetic SEVI. Moreover,
we demonstrate that the semen-meditated enhancement
of HIV-1 infectivity is highly variable and that EGCG
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concentrations in the majority of semen samples. Our
study highlights the high degree of variation of HIV-1
infectivity enhancement by individual semen samples (as
well as its inhibition by EGCG), even of longitudinal
samples originating from identical donors. While EGCG
holds potential as a possible microbicide, these varia-
tions have to be taken into account and further eluci-
dated before therapeutic trials may be conducted.
Methods
Handling of semen and synthetic SEVI
All semen samples were liquefied for 30 min and kept
frozen at -20°C until they were used in the experiments.
PBS supplemented with 100 units/ml penicillin, 100 mg/
ml streptomycin was used to dilute semen as indicated.
A solution of chemically synthesized SEVI was prepared
as described earlier [7]. Briefly, a 5 mg/ml solution of
the peptide corresponding to amino acid residues 248-
286 of PAP (EMBL accession no. AAB60640), in PBS
was agitated at 37°C and 1, 200 rpm for 2-3 days (i.e.
until the solution became turbid) to initiate fibril forma-
tion [7].
Cell culture and HIV infection experiments
To analyze infectivity-modulating effects in semen,
TZM-bl reporter cells, which can be infected with both
R5- and X4-tropic virus and allow the quantification of
HIV infection via an integrated, Tat-responsive HIV-1
LTR-luciferase reporter expression cassette [28,29] were
employed. 10
4 cells were seeded in microtiter wells in a
volume of 100 μl. After 24 h, cells were infected with
HIV-1 (BaL [30], NL4/3 [31] or a primary HIV-1B iso-
late, corresponding to 100 pg p24 BaL) that was prein-
cubated in the presence or absence of semen in the
concentrations indicated in the figure legends with or
without the addition of EGCG for 20 minutes. After 3 h
at 37°C, the cells were washed and further cultured. At
48 h post infection, luciferase activity was determined.
EGCG was obtained from Sigma Aldrich, Germany, and
a stock solution of 10 mM was prepared in PBS and
stored at -20°C. TZM-bl cells and HIV-1 isolates BaL
and NL4/3 were obtained from the NIH AIDS Research
and Reference Reagent Program.
Analysis of cellular toxicity
Cellular viability in presence of EGCG was tested in a
[
3H]-thymidin incorporation assay and a flow cytome-
try-based apoptosis/necrosis assay utilizing Annexin-V
and 7-AAD. For the [
3H]-thymidin incorporation assay,
10
4 TZM-bl cells were seeded in microtiter wells in a
volume of 100 μl. After 24 h, cells were incubated for 3
h in the presence of EGCG at indicated concentrations,
washed and 0.5 μCi [
3H]-thymidin was added. After
further cultivation for 48 h, the cells were harvested on
filters and [
3H]-thymidin icorporation into DNA was
determined by liquid-scintillation counting. For the
Annexin-V/7-AAD Assay, 10
4 TZM-bl cells were seeded
in microtiter wells in a volume of 100 μl. After 24 h,
cells were incubated for 3 h in presence of EGCG in the
indicated concentrations, washed and cultivated further
for 48 h. Then, the cells were trypsinized and stained
with 7-AAD and FITC-labeled Annexin V (both from
BD Biosciences) according to the manufacturers proto-
col. Data were collected on a FACS Canto flow cyt-
ometer (BD Biosciences, Germany).
Electron microscopy
For transmission electron microscopy analysis, semen
and a solution of synthetic SEVI (5 mg/ml) were encap-
sulated in capillary microtubes and processed for ultra-
thin sectioning as described earlier [7,32].
Statistical analysis
We determined the statistical significance of differences
using Student’s t-test analysis as indicated in the figure
legends. Correlations were determined using the two-
tailed Pearson correlation coefficient. Graphpad Prism
version 5 was used for all calculations. For all analyses,
p-values of less than 0.05 were considered significant.
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